Associate Professor Elin Gray Melanoma Research Group School of Medical and Health Sciences Edith Cowan University Perth Western Australia Blood Biomarkers of Cancer AutoAbs Wan et al Nature Reviews Cancer 2017 ID: 913405
Download Presentation The PPT/PDF document "Blood B iomarkers for Diagnosis, Progno..." is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Slide1
Blood
Biomarkers for Diagnosis, Prognosis and Monitoring of Melanoma Patients
Associate Professor Elin GrayMelanoma Research GroupSchool of Medical and Health SciencesEdith Cowan University, Perth, Western Australia
Slide2Blood Biomarkers of Cancer
AutoAbs
Wan et al., Nature Reviews Cancer 2017Alix-Panabieres & Pantel, Nature Biomedical Engineering 2017AuAbsEasily accessibleCan be regularly testedReal-time monitoring
Slide3Cancer Liquid Biopsy – Just from a blood
sampleCancer Liquid Biopsy – Just from a blood sample
MelDxPauline Zaenker
Slide4Autoantibodies as Diagnostic Melanoma Biomarkers
Discovery phase
MelDx trialroutine skin checkZaenker et al., Oncotarget 201884% Specificity79% Sensitivity
Slide5MelDx Study DesignHypothesisAutoantibody positivity in sera using the MelDx test will correspond with histological diagnosis of melanoma via biopsy.Primary Aim
To validate a combination of autoantibodies that provide diagnostic accuracy of 80% or greater in early stage melanoma.Secondary AimTo evaluate whether a history of skin cancers affects the test results.To evaluate the specificity of MelDx for melanoma relative to other skin cancers, other cancers and autoimmune diseases.
Slide6MelDx Study – your input1. In what situation would an additional test (ie
.: a blood test) be useful?How accurate would a test have to be for you to consider using it (what %)?When you are looking for additional diagnostic tools/tests, what is the main factor that influences your decision to implement these?
Slide7Overall requirementsIf you want to get involvedWritten consentOnce-off 2xSST tubes (6ml)Access to biopsy pathology report
collaboration on papers, grants, etc.Contact: Dr. Pauline Zaenker
p.zaenker@ecu.edu.au(08) 6304 2783
Slide8Cancer Liquid Biopsy – Just from a blood
sampleCancer Liquid Biopsy – Just from a blood sample
MelDxPauline ZaenkerZaenker et al., Oncotarget 2018CNV on CTCsAaron Beasley
Beasley et al., JCO Precision Oncology 2018
Non-invasive prognostication of uveal melanoma
Blood test for early detection of melanoma
Khattak et al., The Oncologist 2019
All CD45/CD16
PD-L1
MEL Nucleus
PD-L1 expression on CTCs predicts
pembrolizumab
outcomes
Adnan Khattak
Slide9Circulating Tumour DNA
Cancer Liquid Biopsy – Just from a blood sample
Gray et al., Oncotarget 2015
Slide10Tumour size and metabolic activity correlates with ctDNA shedding
McEvoy et al., BMC cancer 2018MTB: Metabolic Tumour BurdenMTV: Metabolic Tumour Volume
Ashleigh McEvoyZeyad Al-Ogaili
Slide11ctDNA allows non-invasive assessment of genomic alterations of the tumour
Tumour and plasma pairs N=7
2536Tumour PlasmaTruSeq Illumina Custom Melanoma Panel950 amplicons over 30 genes QiaSeq Custom Melanoma Panel950 amplicons over 30 genesUnique Molecular IdentifiersLeslie Calapre
Benhur Amanuel
PathWest
Detection of BRAF mutant melanoma in tissue vs liquid biopsies
Negative
Agreement 66/66 (100%)
Overall Agreement 135/153 (88%)
False Positive 0%
False Negative 12%
Sensitivity 78%
Specificity
100
%
Slide12ctDNA positivity predicts survival of Stage III melanoma patients
Lee et al., Annals of Oncol
2019 (MIA)Tan et al., Annals of Oncol 2019 (PeterMac/Christie)Before SLND After SLND Before SLND Before SLND (Validation cohort)
Slide13Acknowledgements
Study Participants and Healthy Volunteers
Edith Cowan UniversityMelanoma Research Group SCGH and FSH
Michael Millward
Adnan Khattak
Tarek Meniawy
Lydia Warburton
Zeyad
Al-Ogaili
Tim Isaacs
Fred Chen
PathWest
Ben Wood
Nima
Meshba
Tindaro
Giardina
Cleo Robinson
Benhur Amanuel
Peter Johansson
Nicholas Hayward
QIMR
Helen Rizos
Jenny Lee
Macquarie University
Melanoma Institute Australia
Georgina V. Long
Richard A. Scolyer
Matteo S. Carlino
Harvard University
Markus Frank
Ryan Sullivan
Xin Hong
MelDx
Lester Cowell
Christopher Quirk
Tony Caccetta
Stephanie Weston
Prasad Kumarasinghe
Geoffrey Shulman
Daniel Hewitt
Gordon Harloe
Johnny Lo